VitaNova Life Sciences (VNOV) EBITDA Margin (2017 - 2026)

VitaNova Life Sciences has disclosed EBITDA Margin across 7 years of filings, most recently posting 37.99% for Q3 2026.

• EBITDA Margin for Q3 2026 came in at 37.99%, down 677.0% year-over-year; the trailing twelve-month figure through Jul 2026 was 2.66% (down 4861.0% YoY), and the FY2026 annual result was 0.12%, down 4527.0% from the prior year.
• EBITDA Margin for Q3 2026 stood at 37.99%, down from 6.15% in the prior quarter.
• Across five years, EBITDA Margin topped out at 55.41% in Q2 2025 and bottomed at 245.77% in Q1 2023.
• Average EBITDA Margin over 5 years is 17.14%, with a median of 14.23% recorded in 2022.
• The widest annual swing landed in 2023, when EBITDA Margin sank 27549 bps; it then soared 26856 bps in 2024.
• Year by year, EBITDA Margin stood at 26.01% in 2022, then sank by 662 bps to 146.17% in 2023, then jumped by 115 bps to 21.43% in 2024, then rose by 8 bps to 23.22% in 2025, then tumbled by 264 bps to 37.99% in 2026.
• The last three EBITDA Margin figures came in at 37.99% (Q3 2026), 6.15% (Q2 2026), and 6.59% (Q1 2026), per Business Quant data.